A U.S. appeals court upheld the dismissal of a patent-infringement case Bayer filed against Teva Pharmaceutical Industries regarding anthrax drug Cipro, but the three-judge panel expressed concern about the legality of "pay-to-delay" agreements between makers of brand-name and generic drugs. The panel also urged those opposed to such deals to ask for the full court's intervention.

Full Story:

Related Summaries